Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies (Q28200569)

Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin

Europe PubMed Central

title

Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies (English)

0 references

0 references

1 reference

Angel Lanas

1

0 references

Richard Hunt

series ordinal

2

0 references

language of work or name

English

0 references

publication date

2006

0 references

published in

Annals of Medicine

0 references

volume

38

0 references

issue

6

0 references

page(s)

415-28

0 references

cites work

1 reference

https://api.crossref.org/works/10.1080/07853890600925843

Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib

21 April 2017

1 reference

https://api.crossref.org/works/10.1080/07853890600925843

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial

21 April 2017

1 reference

https://api.crossref.org/works/10.1080/07853890600925843

Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs

21 April 2017

1 reference

https://api.crossref.org/works/10.1080/07853890600925843

Nonsteroidal anti-inflammatory drug prescribing: past, present, and future

21 April 2017

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Striking prevalence of over-the-counter nonsteroidal anti-inflammatory drug use in patients with upper gastrointestinal hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

The coxibs, selective inhibitors of cyclooxygenase-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

A randomized trial of aspirin to prevent colorectal adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Nonsteroidal anti-inflammatory drug gastropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Nonsteroidal anti-inflammatory drug-associated dyspepsia: the scale of the problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Prophylactic aspirin and risk of peptic ulcer bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Dual COX Inhibition and Upper Gastrointestinal Damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Clinical Implications of COX-1 and / or COX-2 Inhibition for the Distal Gastrointestinal Tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Helicobacter pylori and gastric cancer: a new paradigm for inflammation-associated epithelial cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Time course and pattern of blood loss with ibuprofen treatment in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Evidence of aspirin use in both upper and lower gastrointestinal perforation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Acute gastrointestinal permeability responses to different non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Global safety of coxibs and NSAIDs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Risk of cardiovascular events associated with selective COX-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Hypochlorhydria induced by a proton pump inhibitor leads to intragastric microbial production of acetaldehyde from ethanol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Assessment of the safety of selective cyclo-oxygenase-2 inhibitors: where are we in 2003?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Economic analysis of strategies in the prevention of non-steroidal anti-inflammatory drug-induced complications in the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

A simple computer program for guiding management of cardiovascular risk factors and prescribing

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600925843

10.1080/07853890600925843

21 January 2018

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

2594643

2594643

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference